{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Complete response and partial response as assessed by RECIST Version 1.1 Criteria. This outcome measure applies only to participants in the dose expansion cohorts.","groups":[{"description":"SBT6050 plus trastuzumab deruxtecan SBT6050: Dosed with 0.45 mg/kg by subcutaneous (SC) injection in 21-day cycles trastuzumab deruxtecan: 6.4 mg/kg by IV infusion in 21-day cycles","id":"OG000","title":"SBT6050 + T-DXd (6.4 mg/kg)"},{"description":"SBT6050 plus tucatinib and trastuzumab SBT6050: Dosed with 0.45 mg/kg by subcutaneous (SC) injection in 21-day cycles tucatinib: 300 mg by mouth (PO) twice daily (BID) trastuzumab: 8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles","id":"OG001","title":"SBT6050 + Tucatinib + Trastuzumab"}],"populationDescription":"No participants were enrolled in the dose expansion cohorts; study was terminated by Sponsor.","reportingStatus":"POSTED","timeFrame":"0 weeks","title":"Number of Participants With an Objective Response Rate","type":"PRIMARY"}